Ebola Cure in Kenya: Stakeholders’ Viewpoints

The promotion of a new program requires many changes and certain evaluations. Cooperation with different people plays an important role in our work. At this moment, the opinions of several groups of people matter to the potential progress of our company.


Lobbyists are activists whose role is to influence the decisions of the government and support or disprove the necessity of legislation. In terms of our project, this group of people finds it necessary to re-evaluate the government attitude to the problem of Ebola cure in Kenya. They believe that the idea to create available pharmaceutical drugs for the local Kenyan population can be rewarded with the time, and they are ready to give a hand.


The opinions of non-governmental organizations remain unclear. Some representatives are ready to pay their attention to the discussion of the current problem. However, some organizations are not confident in the methods and outcomes of this project due to its poor media coverage and the inability to identify the core problem. At this moment, restrictions on patents for AIDS drugs for Kenya that are rooted in the WTO Agreement on TRIPS deprive the population of the opportunity to be freely cured (Sihanya, n.d.). NGOs can take a step and think about their contributions to this problem.

Kenya Government

The government of Kenya is probably one of the weakest stakeholders in this discussion. Regarding research by the World Health Organization (2007) and the achievements of the Brazilian fights against AIDS (Gómez, 2011), even the most serious problems and challenges can be solved in case the government recognizes its impact. The Kenya government aims at promoting special training programs and education to its people in order to prepare them for new significant steps.

Pharmaceutical Company/Patent Holders

Communication with pharmaceutical companies and patent holders has led to positive results. This group of stakeholders believes that the Kenya population deserves the right to free medications, and they are ready to give their legal permission and participate in the development of new drugs in case the government supports this idea and legalizes their activities in the region. Our decision to use the Hosmer problem-solving model helps patent holders to recognize a problem, evaluate different viewpoints, and come to a conclusion to support the developers of a program.

Generic Drug Company (India)

A generic drug manufacturing company in India is able to provide the country with specific antiretroviral drugs and establish appropriate prices. Negotiations have to be continued to discuss all details. Still, the main viewpoint of this group of stakeholders is to support the idea of free drugs for the population in need.


The representatives of the WHO demonstrate their positive attitudes to support the citizens of Kenya. This organization defines Kenya as a developing country whose people are in need of free drugs to deal with AIDS, TB, malaria, and other problems (World Health Organization, 2007). According to its point of view, communication with the local government has to be developed at the international level.

Sick People

Sick people are the most interested group in the development of this project. They believe that their government has to protect their lives and offer opportunities. It is wrong to neglect the social and health needs of people. Therefore, they are ready to participate in medical research and cohort trials in order to earn a chance and be cured or to deserve treatment for family members.


Many activists, including Catholics, would like to support healthcare improvements for the citizens of Kenya. At the same time, they do not find it necessary to support the idea of condom use and gain protection. They want to believe that Kenyans get an opportunity to improve their health, relying on their faith and personal enthusiasm. Unfortunately, the role of such stakeholders can be defined as motivational but not effective because oral support and faith are not always enough to treat a serious disease.


Gómez, E. J. (2011). Why Brazil’s response to AIDS worked. CNN. Web.

Sihanya, B. (n.d.). Patents, parallel importation and compulsory licensing of HIV/AIDS drugs: The experience of Kenya. World Trade Organization. Web.

World Health Organization. (2007). Multi-country regional pooled procurement of medicines. Web.